Work

Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study.

Year: 2009

Type: article

Abstract: A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous, however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated meta-analyses showed an overall reduction in all-cause mortality for PPD-positive individuals on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).

Source: PubMed

Authors: M A Bachhuber, R Gross

Institution: University of Pennsylvania

Language: English

Topic: Tuberculosis Research and Epidemiology

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute of Allergy and Infectious Diseases

Award: Penn Center for AIDS Research